Jung Cassie 4
4 · Aquestive Therapeutics, Inc. · Filed Sep 8, 2025
Insider Transaction Report
Form 4Exit
Jung Cassie
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2025-09-04$3.15/sh+25,000$78,750→ 320,526 total - Exercise/Conversion
Common Stock
[F1]2025-09-04$0.71/sh+25,000$17,658→ 345,526 total - Sale
Common Stock
[F2]2025-09-04$5.00/sh−62,180$310,900→ 283,346 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
[F1][F3]2025-09-04−25,000→ 0 totalExercise: $3.15Exp: 2029-08-09→ Common Stock (25,000 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
[F1][F4]2025-09-04−25,000→ 0 totalExercise: $0.71Exp: 2032-08-05→ Common Stock (25,000 underlying)
Holdings
- 2,000(indirect: By Spouse)
Common Stock
Footnotes (4)
- [F1]This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected.
- [F2]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.
- [F3]This option was granted on August 9, 2019 and is fully vested.
- [F4]This option was granted on August 5, 2022 and is fully vested.
Signature
/s/ Lori Braender, as Attorney-In-Fact|2025-09-08